Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:TypeZero_Technologies
|
| gptkbp:category |
healthcare
diabetes technology |
| gptkbp:CEO |
gptkb:Kevin_Sayer
|
| gptkbp:founded |
1999
|
| gptkbp:founder |
gptkb:Scott_Glenn
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dexcom
|
| gptkbp:industry |
medical devices
|
| gptkbp:market |
global
|
| gptkbp:notableProduct |
gptkb:Dexcom_G6
gptkb:Dexcom_G7 |
| gptkbp:numberOfEmployees |
over 7,000 (2023)
|
| gptkbp:partner |
gptkb:Verily
gptkb:Insulet gptkb:Tandem_Diabetes_Care |
| gptkbp:product |
continuous glucose monitoring systems
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ:DXCM
|
| gptkbp:regulates |
gptkb:FDA
gptkb:CE_Mark |
| gptkbp:revenue |
$2.91 billion (2022)
|
| gptkbp:serves |
diabetes patients
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:DXCM
|
| gptkbp:website |
https://www.dexcom.com/
|
| gptkbp:bfsParent |
gptkb:Glooko_Inc.
|
| gptkbp:bfsLayer |
5
|